読み込み中
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
前日終値
$4.87
+$0.23 · +4.96%
日中の時刻はETです。市場データは遅延する場合があります。
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
日中レンジ
現在 $4.87
52週レンジ
現在 $4.87
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
32
割高
センチメント
65
強気
リスク
64
高リスク
モメンタム
54
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
日中レンジ
現在 $4.87
52週レンジ
現在 $4.87
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上原価 | 3.1万 USD | — | — | — | — |
| 粗利益 | −3.1万 USD | — | — | — | — |
| 研究開発 | 5379.8万 USD | 6152.7万 USD | 5574.3万 USD | 4381.3万 USD | 3248.6万 USD |
| 販売・一般管理 | 2916.8万 USD | 1836.7万 USD | 1468万 USD | 1217.7万 USD | 935.7万 USD |
| 営業費用 | 8296.6万 USD | 7989.4万 USD | 7042.3万 USD | 5599万 USD | 4184.3万 USD |
| 受取利息 | 488万 USD | 548.2万 USD | 487万 USD | 420.8万 USD | 8万 USD |
| 支払利息 | — | — | — | — | 180.7万 USD |
| 減価償却費と償却費 | 3.1万 USD | 3.1万 USD | 3.6万 USD | 3万 USD | 1.3万 USD |
| 営業利益 | −8296.6万 USD | −7989.4万 USD | −7042.3万 USD | −5599万 USD | −4184.3万 USD |
| 純利益 | −7758.6万 USD | −7441.2万 USD | −6845.9万 USD | −5178.7万 USD | −4106万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1287.24万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM979.5万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF477.29万0.00%954億 USD0.05%$235+0.80%
Dimensional - US Small Cap ETFDFAS221.42万0.01%338.69億 USD0.31%$78.35+0.32%
Vanguard Russell 2000 ETFVTWO211.14万0.01%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA189.96万0.01%218.24億 USD0.03%$32.79+0.40%
Fidelity Enhanced Small Cap ETFFESM178.81万0.03%64.1億 USD0.28%$45.46+0.46%
Janus Henderson Small Cap Growth Alpha ETFJSML124.06万0.34%3.61億 USD0.30%$87.477+1.00%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAFidelity Enhanced Small Cap ETFFESMJanus Henderson Small Cap Growth Alpha ETFJSMLAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
